HR-1193-117
Became Public Law No: 117-244.
Sponsored by Andy Barr (R-KY)
What it does
This law directs the National Institutes of Health (NIH) to conduct or support research on valvular heart disease — a condition where one or more of the heart's valves are damaged or diseased. It requires the National Heart, Lung, and Blood Institute (NHLBI) to hold a workshop specifically on mitral valve prolapse. It also requires the Department of Health and Human Services (HHS) to develop best practices for treating valvular heart disease and allows HHS to run additional education and awareness programs on the disease.
Who benefits
People diagnosed with valvular heart disease, including the estimated 5 million Americans with mitral valve prolapse. Patients who may receive more consistent, evidence-based care if best practices are widely adopted. Medical researchers who would gain access to NIH funding and institutional support for cardiovascular studies. Healthcare providers who would receive clearer clinical guidance. Underdiagnosed populations — particularly women, who are disproportionately affected by mitral valve prolapse — who may benefit from increased awareness.
Who is hurt
No group faces a direct financial or legal burden from this law. Taxpayers broadly fund any NIH, NHLBI, and HHS activities authorized by the bill, though no specific appropriation amount is stated in the text. Private insurers or healthcare systems could face indirect pressure to align with newly developed best practices, potentially affecting coverage decisions or treatment protocols.
Supporters argue
Supporters argue that valvular heart disease is a serious and underrecognized condition affecting millions of Americans, yet it has historically received less research attention and funding than other cardiovascular diseases. They contend that directing NIH and NHLBI to study the disease and convene experts would produce evidence-based best practices that could standardize care, reduce misdiagnosis, and ultimately save lives. Supporters also argue that the bill's focus on education and awareness would help patients — especially women, who are more frequently affected by mitral valve prolapse — get diagnosed and treated earlier, reducing long-term health complications and hospitalizations. They note the law passed with broad bipartisan support, reflecting consensus that targeted federal research coordination fills a genuine gap in public health infrastructure.
Opponents argue
Opponents argue that the federal government already funds broad cardiovascular research through NIH and NHLBI, and that singling out one disease category through legislation sets a precedent where Congress, rather than scientific peer review, drives research prioritization. They contend that directing agency resources toward a specific condition may divert funding and institutional attention away from other diseases that could have a greater public health impact per dollar spent. Opponents may also argue that developing "best practices" through an HHS administrative process, rather than through independent medical bodies, risks politicizing clinical guidance and could produce standards that lag behind rapidly evolving medical evidence. Finally, critics note the bill does not authorize a specific funding amount, leaving its practical impact dependent on future appropriations that may never materialize.
Constitutional context
Congress enacted this law under the Spending Clause (Article I, Section 8), which grants broad authority to fund research and public health programs through federal agencies. The Commerce Clause also provides a basis for federal involvement in healthcare markets. Because the law directs existing agencies (NIH, NHLBI, HHS) to conduct research and develop guidance — rather than mandating individual behavior or imposing conditions on states — it does not raise the spending coercion concerns identified in NFIB v. Sebelius (2012). No individual mandate or purchase requirement is involved. The post-Loper Bright environment means any HHS "best practices" guidance could face independent judicial scrutiny if challenged as exceeding statutory authority, though guidance documents typically carry less legal force than binding rules.
Checks and balances
The executive branch (NIH, NHLBI, and HHS) gains discretionary authority to conduct research, convene workshops, and develop best practices. Congress retains the power of the purse — no funds are automatically appropriated, so the law's implementation depends on future congressional appropriations. The legislative branch also retains oversight authority over agency activities authorized by the bill.
Historical precedent
The HEARTS Act (2016) and the National Heart, Lung, and Blood Institute Act similarly directed NIH and NHLBI to prioritize specific cardiovascular research areas. The Affordable Care Act (2010) also established federal authority to develop and disseminate clinical best practices through HHS.